MGNX
MacroGenics, Inc.NASDAQHealthcare$3.07+5.86%ClosedMarket Cap: $195.1M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.61
P/S
1.35
EV/EBITDA
-3.83
DCF Value
$-68.09
FCF Yield
-41.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
71.1%
Operating Margin
-48.7%
Net Margin
-49.9%
ROE
-120.2%
ROA
-29.1%
ROIC
-33.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $41.2M | 62.4% | $-12.1M | $-14.2M | $-0.22 | — |
| FY 2025 | $149.5M | 71.1% | $-72.8M | $-74.6M | $-1.18 | — |
| Q3 2025 | $72.8M | 81.6% | $18.6M | $16.8M | $0.27 | — |
| Q2 2025 | $22.2M | 60.0% | $-36.8M | $-36.3M | $-0.57 | — |
| Q1 2025 | $13.2M | 59.1% | $-42.6M | $-41.0M | $-0.65 | — |
| Q4 2024 | $17.7M | 69.0% | $-52.8M | $-15.4M | $-0.25 | — |
| FY 2024 | $148.3M | 91.7% | $-110.6M | $-67.0M | $-1.07 | — |
| Q3 2024 | $110.7M | 61.7% | $54.2M | $56.3M | $0.90 | — |
| Q2 2024 | $10.8M | 73.9% | $-58.2M | $-55.7M | $-0.89 | — |
| Q1 2024 | $9.1M | 76.8% | $-53.8M | $-52.2M | $-0.84 | — |
| Q4 2023 | $10.7M | -343.2% | $-49.4M | $-46.1M | $-0.74 | — |
| FY 2023 | $57.2M | 85.6% | $-168.2M | $-9.1M | $-0.15 | — |